dc.contributor.author	Bichler, Shimshon
dc.contributor.author	Nitzan, Jonathan
dc.date.accessioned	2022-10-28T15:48:26Z
dc.date.available	2022-10-28T15:48:26Z
dc.date.issued	2021
dc.description	capitalization finance pharmaceutical power profit
dc.description.abstract	A lot has been written on the imminent decline of pharmaceuticals: their falling production, reduced R&D, declining innovation, the opioid crisis, patent cliffs, biting competition from generic drugs, growing opposition to IPR. The list goes on. Judging by the yardsticks that matter the most, though – namely, the companies’ relative profit and relative capitalization – pharmaceuticals are doing just fine. In fact, based on these yardsticks, they remain the most powerful corporate sector of all.
dc.identifier.citation	Pharmaceuticals: Beating the Hell Out of the Average. Bichler, Shimshon and Nitzan, Jonathan. (2021). Research Note. June. pp. 1-5. (Article - Working Paper; English).
dc.identifier.uri	http://hdl.handle.net/10315/39819
dc.title	Pharmaceuticals: Beating the Hell Out of the Average
dc.type	Working Paper

Pharmaceuticals: Beating the Hell Out of the Average

Files